争议事件
以下收录公开来源中与该品牌相关的争议事件。列出一条并不表示过错已经证实。
返回词条共 27 条 · 第 2 / 2 页
2019
拜耳因Supradyn Kids广告被罚款
罚款或处罚
匈牙利竞争委员会代理机构对拜耳处以2万欧元罚款,并命令其停止传播Supradyn Kids补充剂产品的相关信息。委员会认定一则推广Supradyn Kids复合维生素的电视广告涉及对消费者的不公平商业行为。
来源摘录
“The acting Competition Council finds that Bayer Hungária Kft has conducted unfair commercial practices against consumers in a television ad promoting the Supradyn Kids multivitamin published between November 14, 2016 and February 26, 2017,” the order stated.
In fining the firm €20,000 (HUF 7m) the acting Competition Council ordered Bayer to “terminate all means of communication of the Supradyn Kids multivitamin omega 3 and choline dietary supplement products”.
2018
2013
拜耳就Finacea仿制药起诉格兰马克
提起诉讼
格兰马克提交Finacea仿制药的美国申请后,拜耳及其子公司Intendis和Intraserv起诉格兰马克。拜耳称该产品侵犯Finacea专利,并寻求法院命令阻止专利到期前商业化。
来源摘录
However, Bayer – alongside its subsidiaries Intendis and Intraserv – claims Glenmark’s product infringes on Finacea’s patent, and it wants a legal order preventing Glenmark from commercialising generic azeliac acid gel until this time.
Bayer has launched a lawsuit against Glenmark Generics after the India-based firm filed for US approval of a generic version of skin disorder treatment Finacea.
2001
1980
1960
1939